{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:30:12Z","timestamp":1759336212889},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1007\/s11940-004-0024-5","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T19:48:03Z","timestamp":1180986483000},"page":"155-161","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inflammatory myopathies"],"prefix":"10.1007","volume":"6","author":[{"given":"Patrick M.","family":"Grogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"24_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peters JB: Polymyositis and dermatomyositis: part 1. N Engl J Med 1975, 292:344\u2013347.","journal-title":"N Engl J Med"},{"key":"24_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peters JB: Polymyositis and dermatomyositis: part 2. N Engl J Med 1975, 292:403\u2013407.","journal-title":"N Engl J Med"},{"key":"24_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-2002-33047","volume":"22","author":"JT Kissel","year":"2002","unstructured":"Kissel JT: Misunderstandings, misperceptions, and mistakes in the management of inflammatory myopathies. Seminars 2002, 22:41\u201351. A recent, well-written, clinically oriented review of the inflammatory myopathies. It uses a case oriented approach that details the pitfalls of using the \u201cold\u201d diagnostic method, and highlights the latest clinical research.","journal-title":"Seminars"},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","volume":"59","author":"SA Greenberg","year":"2002","unstructured":"Greenberg SA, Sanoudou D, Haslett JN, et al.: Molecular profiles of inflammatory myopathies. Neurology 2002, 59:1170\u20131182.","journal-title":"Neurology"},{"key":"24_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003, 362:971\u2013982. This is the most recent review on these disorders. It provides a detailed overview of the clinical presentation and diagnosis, and does a particularly good job in describing the complex immunopathogenesis of PM and DM.","journal-title":"Lancet"},{"key":"24_CR6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11940-003-0025-9","volume":"5","author":"HR Briemberg","year":"2003","unstructured":"Briemberg HR, Amato AA: Dermatomyositis and polymyositis. Curr Treat Options Neurol 2003, 5:349\u2013356.","journal-title":"Curr Treat Options Neurol"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0733-8619(05)70337-6","volume":"15","author":"AA Amato","year":"1997","unstructured":"Amato AA, Barohn RJ: Idiopathic inflammatory myopathies. Neurol Clin 1997, 15:615\u2013648.","journal-title":"Neurol Clin"},{"key":"24_CR8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/0002-9343(91)90009-M","volume":"91","author":"P Cherin","year":"1991","unstructured":"Cherin P, Herson S, Wechsler B, et al.: Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991, 91:262\u2013168.","journal-title":"Am J Med"},{"key":"24_CR10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch TW, Worthington JW, Combs JJ, et al.: Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 1980, 92:365\u2013369.","journal-title":"Ann Intern Med"},{"key":"24_CR11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.45.7.1302","volume":"45","author":"RJ Barohn","year":"1995","unstructured":"Barohn RJ, Amato AA, Sahenk Z, et al.: Inclusion body myositis: explanation for poor response to therapy. Neurology 1995, 45:1302\u20131304.","journal-title":"Neurology"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, et al.: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705\u2013713.","journal-title":"Ann Neurol"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter MC, Lochmuller H, Toepfer M, et al.: High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000, 247:22\u201328.","journal-title":"J Neurol"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ana.10121","volume":"51","author":"UA Badrising","year":"2002","unstructured":"Badrising UA, Maat-Schieman MLC, Ferrari MD, et al.: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51:369\u2013372.","journal-title":"Ann Neurol"},{"key":"24_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, et al.: A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001, 56:323\u2013327.","journal-title":"Neurology"},{"key":"24_CR16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","volume":"57","author":"Muscle Study Group","year":"2001","unstructured":"Muscle Study Group: Randomized pilot trial of beta-INF1a (Avonex) in patients with inclusion body myositis. Neurology 2001, 57:1566\u20131570.","journal-title":"Neurology"},{"key":"24_CR17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","volume":"58","author":"SB Rutkove","year":"2002","unstructured":"Rutkove SB, Parker RA, Nardin RA, et al.: A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002, 58:1081\u20131087.","journal-title":"Neurology"},{"key":"24_CR18","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B: A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998, 50:1778\u20131783.","journal-title":"Neurology"},{"key":"24_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/030097400447679","volume":"29","author":"H Alexanderson","year":"2000","unstructured":"Alexanderson H, Stenstrom CH, Jenner G, Lundberg I: The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 2000, 29:295\u2013301.","journal-title":"Scand J Rheumatol"},{"key":"24_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0960-8966(98)00126-6","volume":"9","author":"J DeBleecker","year":"1999","unstructured":"DeBleecker J, Meire V, Declercq W, Van Aken E: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999, 9:239\u2013246.","journal-title":"Neuromuscul Disord"},{"key":"24_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJD Hengstman","year":"2003","unstructured":"Hengstman GJD, Van den Hoogen FHJ, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50:10\u201315.","journal-title":"Eur Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-004-0024-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0024-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-004-0024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T09:52:27Z","timestamp":1660902747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-004-0024-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s11940-004-0024-5","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}